116 related articles for article (PubMed ID: 34520770)
61. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
62. Lapatinib inhibits the activation of NF-κB through reducing phosphorylation of IκB-α in breast cancer cells.
Ma C; Zuo W; Wang X; Wei L; Guo Q; Song X
Oncol Rep; 2013 Feb; 29(2):812-8. PubMed ID: 23229346
[TBL] [Abstract][Full Text] [Related]
63. A new pyrrole based small molecule from Tinospora cordifolia induces apoptosis in MDA-MB-231 breast cancer cells via ROS mediated mitochondrial damage and restoration of p53 activity.
Rashmi KC; Harsha Raj M; Paul M; Girish KS; Salimath BP; Aparna HS
Chem Biol Interact; 2019 Feb; 299():120-130. PubMed ID: 30543781
[TBL] [Abstract][Full Text] [Related]
64. Verrucarin A induces apoptosis through ROS-mediated EGFR/MAPK/Akt signaling pathways in MDA-MB-231 breast cancer cells.
Palanivel K; Kanimozhi V; Kadalmani B; Akbarsha MA
J Cell Biochem; 2014 Nov; 115(11):2022-32. PubMed ID: 24963595
[TBL] [Abstract][Full Text] [Related]
65. Apigenin induces apoptosis via extrinsic pathway, inducing p53 and inhibiting STAT3 and NFκB signaling in HER2-overexpressing breast cancer cells.
Seo HS; Choi HS; Kim SR; Choi YK; Woo SM; Shin I; Woo JK; Park SY; Shin YC; Ko SG
Mol Cell Biochem; 2012 Jul; 366(1-2):319-34. PubMed ID: 22527937
[TBL] [Abstract][Full Text] [Related]
66. E-cadherin is required for metastasis in multiple models of breast cancer.
Padmanaban V; Krol I; Suhail Y; Szczerba BM; Aceto N; Bader JS; Ewald AJ
Nature; 2019 Sep; 573(7774):439-444. PubMed ID: 31485072
[TBL] [Abstract][Full Text] [Related]
67. Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer.
Kim JY; Cho Y; Oh E; Lee N; An H; Sung D; Cho TM; Seo JH
Cancer Lett; 2016 Aug; 379(1):39-48. PubMed ID: 27238567
[TBL] [Abstract][Full Text] [Related]
68. Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer.
Sabbaghi M; Gil-Gómez G; Guardia C; Servitja S; Arpí O; García-Alonso S; Menendez S; Arumi-Uria M; Serrano L; Salido M; Muntasell A; Martínez-García M; Zazo S; Chamizo C; González-Alonso P; Madoz-Gúrpide J; Eroles P; Arribas J; Tusquets I; Lluch A; Pandiella A; Rojo F; Rovira A; Albanell J
Clin Cancer Res; 2017 Nov; 23(22):7006-7019. PubMed ID: 28821558
[No Abstract] [Full Text] [Related]
69. PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma.
Aslam MI; Abraham J; Mansoor A; Druker BJ; Tyner JW; Keller C
Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6383-8. PubMed ID: 24733895
[TBL] [Abstract][Full Text] [Related]
70. Quercetin induces caspase-dependent extrinsic apoptosis through inhibition of signal transducer and activator of transcription 3 signaling in HER2-overexpressing BT-474 breast cancer cells.
Seo HS; Ku JM; Choi HS; Choi YK; Woo JK; Kim M; Kim I; Na CH; Hur H; Jang BH; Shin YC; Ko SG
Oncol Rep; 2016 Jul; 36(1):31-42. PubMed ID: 27175602
[TBL] [Abstract][Full Text] [Related]
71. Targeting receptor tyrosine kinase EphB4 in cancer therapy.
Chen Y; Zhang H; Zhang Y
Semin Cancer Biol; 2019 Jun; 56():37-46. PubMed ID: 28993206
[TBL] [Abstract][Full Text] [Related]
72. Loss of EphB4 receptor tyrosine kinase protein expression during carcinogenesis of the human breast.
Berclaz G; Flütsch B; Altermatt HJ; Rohrbach V; Djonov V; Ziemiecki A; Dreher E; Andres AC
Oncol Rep; 2002; 9(5):985-9. PubMed ID: 12168060
[TBL] [Abstract][Full Text] [Related]
73. Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth.
Chen J; Kinoshita T; Sukbuntherng J; Chang BY; Elias L
Mol Cancer Ther; 2016 Dec; 15(12):2835-2844. PubMed ID: 27678331
[TBL] [Abstract][Full Text] [Related]
74. EPHA5 mediates trastuzumab resistance in HER2-positive breast cancers through regulating cancer stem cell-like properties.
Li Y; Chu J; Feng W; Yang M; Zhang Y; Zhang Y; Qin Y; Xu J; Li J; Vasilatos SN; Fu Z; Huang Y; Yin Y
FASEB J; 2019 Apr; 33(4):4851-4865. PubMed ID: 30620624
[TBL] [Abstract][Full Text] [Related]
75. The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.
Ferguson BD; Liu R; Rolle CE; Tan YH; Krasnoperov V; Kanteti R; Tretiakova MS; Cervantes GM; Hasina R; Hseu RD; Iafrate AJ; Karrison T; Ferguson MK; Husain AN; Faoro L; Vokes EE; Gill PS; Salgia R
PLoS One; 2013; 8(7):e67668. PubMed ID: 23844053
[TBL] [Abstract][Full Text] [Related]
76. Expression of Ephb2 and Ephb4 in breast carcinoma.
Wu Q; Suo Z; Risberg B; Karlsson MG; Villman K; Nesland JM
Pathol Oncol Res; 2004; 10(1):26-33. PubMed ID: 15029258
[TBL] [Abstract][Full Text] [Related]
77. Lapatinib inhibits doxorubicin induced migration of HER2-positive breast cancer cells.
Chintalaramulu N; Vadivelu R; Nguyen NT; Cock IE
Inflammopharmacology; 2020 Oct; 28(5):1375-1386. PubMed ID: 32378049
[TBL] [Abstract][Full Text] [Related]
78. Design, synthesis, and computational validation of novel compounds selectively targeting HER2-expressing breast cancer.
Elseginy SA; Hamdy R; Menon V; Almehdi AM; El-Awady R; Soliman SSM
Bioorg Med Chem Lett; 2020 Dec; 30(24):127658. PubMed ID: 33130288
[TBL] [Abstract][Full Text] [Related]
79. 13-Ethylberberine Induces Apoptosis through the Mitochondria-Related Apoptotic Pathway in Radiotherapy-Resistant Breast Cancer Cells.
Jin H; Ko YS; Park SW; Chang KC; Kim HJ
Molecules; 2019 Jul; 24(13):. PubMed ID: 31277363
[TBL] [Abstract][Full Text] [Related]
80. Fatty acid synthase inhibition by amentoflavone suppresses HER2/neu (erbB2) oncogene in SKBR3 human breast cancer cells.
Lee JS; Sul JY; Park JB; Lee MS; Cha EY; Song IS; Kim JR; Chang ES
Phytother Res; 2013 May; 27(5):713-20. PubMed ID: 22767439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
